Risk factors for inferior progression-free survival following HD-ASCT
. | P . |
|---|---|
| All patients | |
| Univariate analysis | |
| At least 2 prior CT regimens | < .001 |
| IF or AD at protocol/entry | .02 |
| Use of blood (vs BM)* | .05 |
| Use of 7-8 induction drugs | .08 |
| Multivariate analysis | |
| At least 2 prior CT regimens | < .001 |
| Patients in first relapse | |
| Univariate analysis | |
| At least 2 prior CT regimens | .006 |
| Use of blood (vs BM)* | .004 |
| Extranodal disease at relapse | .01 |
| B symptoms at relapse | .03 |
| Multivariate analysis | |
| At least 2 prior CT regimens | .004 |
| Extranodal disease at relapse | .009 |
| Bulky disease at relapse | .05 |
| B symptoms at relapse | .09 |
. | P . |
|---|---|
| All patients | |
| Univariate analysis | |
| At least 2 prior CT regimens | < .001 |
| IF or AD at protocol/entry | .02 |
| Use of blood (vs BM)* | .05 |
| Use of 7-8 induction drugs | .08 |
| Multivariate analysis | |
| At least 2 prior CT regimens | < .001 |
| Patients in first relapse | |
| Univariate analysis | |
| At least 2 prior CT regimens | .006 |
| Use of blood (vs BM)* | .004 |
| Extranodal disease at relapse | .01 |
| B symptoms at relapse | .03 |
| Multivariate analysis | |
| At least 2 prior CT regimens | .004 |
| Extranodal disease at relapse | .009 |
| Bulky disease at relapse | .05 |
| B symptoms at relapse | .09 |
HD-ASCT indicates high-dose chemotherapy and autologous stem cell transplantation; CT, chemotherapy; IF, induction failure; AD, advanced disease; BM, bone marrow.
As graft source.